News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

co.don AG (DX:CNW) On The List Of Growth Champions Again In 2017



11/17/2016 9:54:31 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
- Eighth place in the category Chemistry and Pharma

- Second year co.don included in prestigious list of growth companies

Teltow/Germany, 17 November 2016 – co.don AG has been included in the FOCUS list of Growth Champions 2017. Growth Champions compiles a list of the 500 German companies with the highest revenue growth in the past four years. And co.don AG comes in eighth place in the category Chemistry and Pharma.

Dirk Hessel, CEO of co.don AG: "Our aim is to apply the regenerative therapy options from co.don to defer joint replacement or ideally to avoid it altogether in order to maintain everyday routines and quality of life. We are delighted that FOCUS has again selected co.don as a growth champion. This distinction is due to the performance of all our staff, who I would like to thank sincerely on behalf of the Executive Board. To date we have only operated in the German market. For autumn next year we are expecting EU marketing authorisation for our main product. So co.don AG's greatest growth potential is still ahead of us."

About co.don® AG: Berlin-based co.don AG develops, produces and markets in Germany autologous cell therapies for the minimally invasive repair of cartilage damage to joints following traumatic or degenerative defects. co.don condrosphere® is a cell therapy product that uses only the patient's own cartilage cells ("autologous chondrocytes"). co.don condrosphere® has been approved by the German federal agency PEI in accordance with Section 4b of the German Pharmaceuticals Act (AMG) and is currently undergoing Phase II and III clinical trials to obtain European marketing authorisation. co.don condrosphere® has been used for more than 10 years in over 120 clinics to treat more than 10,000 patients. In Germany the statutory health insurance companies have paid for the treatment of knee and hip joints since 2007 and for the treatment of vertebral joints since 2008. The shares in co.don AG are listed on the Frankfurt Stock Exchange (ISIN: DE000A1K0227). Executive Board: Dirk Hessel (CEO), Ralf M. Jakobs (CFO).

Read at BioSpace.com


comments powered by Disqus
co.don AG
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES